Status:
TERMINATED
An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend
Lead Sponsor:
Pfizer
Conditions:
Kidney Failure
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
This is a study to investigate the pharmacokinetics, safety and tolerability of intravenous voriconazole and SBECD in patients with moderate renal insufficiency
Detailed Description
The study was put on hold after the first subject was enrolled and experienced a serious adverse event (SAE) of renal failure chronic after receiving his I.V. dose on Day 1. The study was taken off ho...
Eligibility Criteria
Inclusion
- Patients with moderate renal insufficiency
Exclusion
- Active infection
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2005
Estimated Enrollment :
1 Patients enrolled
Trial Details
Trial ID
NCT00150319
Start Date
June 1 2005
End Date
October 1 2005
Last Update
September 29 2008
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Orleans, Louisiana, United States, 70118
2
Pfizer Investigational Site
New Orleans, Louisiana, United States, 70119
3
Pfizer Investigational Site
Minneapolis, Minnesota, United States, 55404
4
Pfizer Investigational Site
Knoxville, Tennessee, United States, 37920